Grifols SA GRFS

NAS: GRFS | ISIN: US3984384087   30/04/2025
6,950 USD (-1,84%)
(-1,84%)   30/04/2025

19 april 2024 · Grifols 2023 Annual Report on Form 20-F filed with the SEC · Persbericht

18 april 2023 · Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 · Persbericht

6 maart 2023 · Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease · Persbericht

3 november 2022 · Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1 · Persbericht

3 oktober 2022 · Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson · Persbericht

7 september 2022 · Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada · Persbericht

29 april 2022 · Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 · Persbericht

25 april 2022 · Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation · Persbericht

10 maart 2022 · XEMBIFY® de Grifols reçoit des approbations européennes, élargissant l'accès à des thérapies innovantes pour les patients · Persbericht

2 maart 2022 · Grifols partners with Feeding America® to help address hunger in the U.S. · Persbericht

24 februari 2022 · Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis · Persbericht

30 november 2021 · Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma · Persbericht

4 november 2021 · Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals · Persbericht

19 oktober 2021 · Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines · Persbericht

1 juni 2021 · Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B · Persbericht

19 mei 2021 · Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona · Persbericht

28 april 2021 · Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics · Persbericht

15 april 2021 · Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 · Persbericht

9 april 2021 · Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 · Persbericht

2 april 2021 · Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 · Persbericht

Mijn selecties